{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:06:24Z","timestamp":1790341584855,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"34","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T00:00:00Z","timestamp":1530748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.vaccine.2018.06.064","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T19:09:08Z","timestamp":1532113748000},"page":"5194-5203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Protective efficacy of monovalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses"],"prefix":"10.1016","volume":"36","author":[{"given":"Wei-Gang","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Steigerwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Kalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Volkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Noll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Les P.","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.06.064_b0005","series-title":"Eighth report of the International Committee on Taxonomy and Nomenclature of Viruses","first-page":"999","article-title":"Family togaviridae in virus taxonomy: classification and nomenclature of viruses","author":"Weaver","year":"2005"},{"key":"10.1016\/j.vaccine.2018.06.064_b0010","series-title":"Togaviridae: the viruses and their replication","first-page":"1001","author":"Kuhn","year":"2007"},{"issue":"6","key":"10.1016\/j.vaccine.2018.06.064_b0015","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1016\/j.ijid.2011.03.005","article-title":"Viral infections in workers in hospital and research laboratory settings: a comparative review of infection modes and respective biosafety aspects","volume":"15","author":"Pedrosa","year":"2011","journal-title":"Int J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2018.06.064_b0020","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.coviro.2012.02.014","article-title":"Nonhuman primate models of encephalitic alphavirus infection: historical review and future perspectives","volume":"2","author":"Dupuy","year":"2012","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2018.06.064_b0025","unstructured":"VEE virus- Biological Weapons - GlobalSecurity.org <http:\/\/www.globalsecurity.org\/wmd\/intro\/bio_vee.htm>."},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2018.06.064_b0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0166-3542(02)00203-6","article-title":"Viruses of the bunya- and togaviridae families: potential as bioterrorism agents and means of control","volume":"57","author":"Sidwell","year":"2003","journal-title":"Antiviral Res"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2018.06.064_b0035","first-page":"375","article-title":"The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)","volume":"167","author":"Mayr","year":"1978","journal-title":"Zentralbl Bakteriol B"},{"issue":"7","key":"10.1016\/j.vaccine.2018.06.064_b0040","first-page":"1795","article-title":"Repeated high-dose (5\u00d710(8) TCID50) toxicity study of a third generation smallpox vaccine (IMVAMUNE) in New Zealand white rabbits","volume":"12","author":"Tree","year":"2016","journal-title":"Human Vacc Immunotherap"},{"issue":"23","key":"10.1016\/j.vaccine.2018.06.064_b0045","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.vaccine.2014.02.043","article-title":"Phase II randomized, double-blinded comparison of a single high dose (5\u00d710(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1\u00d710(8) TCID50) in healthy vaccinia-naive individuals","volume":"32","author":"Frey","year":"2014","journal-title":"Vaccine"},{"issue":"29","key":"10.1016\/j.vaccine.2018.06.064_b0050","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.vaccine.2013.04.050","article-title":"Safety and immunogenicity of IMVAMUNE(R) smallpox vaccine using different strategies for a post event scenario","volume":"31","author":"Frey","year":"2013","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2018.06.064_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138348","article-title":"A Multicenter, open-label, controlled phase II study to evaluate safety and immunogenicity of MVA smallpox vaccine (IMVAMUNE) in 18\u201340 year old subjects with diagnosed atopic dermatitis","volume":"10","author":"Greenberg","year":"2015","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.vaccine.2018.06.064_b0060","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/infdis\/jis753","article-title":"Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects","volume":"207","author":"Greenberg","year":"2013","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2018.06.064_b0065","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.vaccine.2005.11.022","article-title":"Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine","volume":"24","author":"Vollmar","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2018.06.064_b0070","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2009.11.030","article-title":"A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE","volume":"28","author":"von Krempelhuber","year":"2010","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.06.064_b0075","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/1568005033481123","article-title":"Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery","volume":"3","author":"Sutter","year":"2003","journal-title":"Curr Drug Targets Infect Disord"},{"issue":"3","key":"10.1016\/j.vaccine.2018.06.064_b0080","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/156652311795684731","article-title":"MVA and NYVAC as vaccines against emergent infectious diseases and cancer","volume":"11","author":"Gomez","year":"2011","journal-title":"Curr Gene Ther"},{"issue":"8","key":"10.1016\/j.vaccine.2018.06.064_b0085","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.addr.2006.05.005","article-title":"Recombinant viral vectors: cancer vaccines","volume":"58","author":"Harrop","year":"2006","journal-title":"Adv Drug Delivery Rev"},{"issue":"6","key":"10.1016\/j.vaccine.2018.06.064_b0090","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1128\/JVI.03418-13","article-title":"A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection","volume":"88","author":"Garcia-Arriaza","year":"2014","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2018.06.064_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003101","article-title":"Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge","volume":"8","author":"van den Doel","year":"2014","journal-title":"PLoS Neglected Trop Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2018.06.064_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002970","article-title":"A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice","volume":"8","author":"Weger-Lucarelli","year":"2014","journal-title":"PLoS Neglected Trop Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2018.06.064_b0105","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1586\/14760584.7.7.889","article-title":"Clinical development of MVA-based therapeutic cancer vaccines","volume":"7","author":"Acres","year":"2008","journal-title":"Exp Rev Vacc."},{"issue":"8","key":"10.1016\/j.vaccine.2018.06.064_b0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073511","article-title":"A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses","volume":"8","author":"Wennier","year":"2013","journal-title":"PloS One"},{"issue":"17","key":"10.1016\/j.vaccine.2018.06.064_b0115","doi-asserted-by":"crossref","first-page":"8743","DOI":"10.1128\/JVI.00604-10","article-title":"Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses","volume":"84","author":"Baur","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.06.064_b0120","first-page":"77","article-title":"Construction and isolation of recombinant MVA","volume":"269","author":"Staib","year":"2004","journal-title":"Meth Mole Biol"},{"issue":"22","key":"10.1016\/j.vaccine.2018.06.064_b0125","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1016\/j.vaccine.2007.03.042","article-title":"Complete protection of mice against a lethal dose challenge of western equine encephalitis virus after immunization with an adenovirus-vectored vaccine","volume":"25","author":"Wu","year":"2007","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.06.064_b0130","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.4049\/jimmunol.118.3.1070","article-title":"Role of the immune response in recovery from Sindbis virus encephalitis in mice","volume":"118","author":"Griffin","year":"1977","journal-title":"J Immunol"},{"issue":"001","key":"10.1016\/j.vaccine.2018.06.064_b0135","first-page":"2157","article-title":"Vaccine development for biothreat alphaviruses","volume":"S1","author":"Spurgers","year":"2011","journal-title":"J Bioterr Biodef"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2018.06.064_b0140","doi-asserted-by":"crossref","first-page":"D80","DOI":"10.1016\/j.vaccine.2009.07.095","article-title":"Vaccines for Venezuelan equine encephalitis","volume":"27","author":"Paessler","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2018.06.064_b0145","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1006\/viro.1995.1458","article-title":"Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1","volume":"212","author":"Davis","year":"1995","journal-title":"Virology"},{"issue":"24","key":"10.1016\/j.vaccine.2018.06.064_b0150","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1016\/j.vaccine.2004.12.023","article-title":"Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus","volume":"23","author":"Reed","year":"2005","journal-title":"Vaccine"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2018.06.064_b0155","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1016\/S0264-410X(03)00328-1","article-title":"Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models","volume":"21","author":"Pratt","year":"2003","journal-title":"Vaccine"},{"issue":"27\u201328","key":"10.1016\/j.vaccine.2018.06.064_b0160","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1016\/j.vaccine.2008.04.044","article-title":"Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates","volume":"26","author":"Fine","year":"2008","journal-title":"Vaccine"},{"issue":"49","key":"10.1016\/j.vaccine.2018.06.064_b0165","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1016\/j.vaccine.2009.09.013","article-title":"Telemetric analysis to detect febrile responses in mice following vaccination with a live-attenuated virus vaccine","volume":"27","author":"Martin","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2018.06.064_b0170","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1128\/JVI.80.6.2784-2796.2006","article-title":"Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals vaccinated with chimeric SIN\/VEE viruses","volume":"80","author":"Paessler","year":"2006","journal-title":"J Virol"},{"issue":"17","key":"10.1016\/j.vaccine.2018.06.064_b0175","doi-asserted-by":"crossref","first-page":"9278","DOI":"10.1128\/JVI.77.17.9278-9286.2003","article-title":"Recombinant sindbis\/Venezuelan equine encephalitis virus is highly attenuated and immunogenic","volume":"77","author":"Paessler","year":"2003","journal-title":"J Virol"},{"issue":"43","key":"10.1016\/j.vaccine.2018.06.064_b0180","doi-asserted-by":"crossref","first-page":"7573","DOI":"10.1016\/j.vaccine.2007.07.061","article-title":"Chimeric Sindbis\/eastern equine encephalitis vaccine candidates are highly attenuated and immunogenic in mice","volume":"25","author":"Wang","year":"2007","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2018.06.064_b0185","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1016\/j.vaccine.2009.05.011","article-title":"Chimeric alphavirus vaccine candidates protect mice from intranasal challenge with western equine encephalitis virus","volume":"27","author":"Atasheva","year":"2009","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2018.06.064_b0190","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.vaccine.2013.01.014","article-title":"A chimeric Sindbis-based vaccine protects cynomolgus macaques against a lethal aerosol challenge of eastern equine encephalitis virus","volume":"31","author":"Roy","year":"2013","journal-title":"Vaccine"},{"issue":"46","key":"10.1016\/j.vaccine.2018.06.064_b0195","doi-asserted-by":"crossref","first-page":"7345","DOI":"10.1016\/j.vaccine.2010.09.005","article-title":"Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates","volume":"28","author":"Dupuy","year":"2010","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2018.06.064_b0200","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1128\/CVI.00030-11","article-title":"A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates","volume":"18","author":"Dupuy","year":"2011","journal-title":"Clin Vacc Immunol: CVI"},{"issue":"33","key":"10.1016\/j.vaccine.2018.06.064_b0205","doi-asserted-by":"crossref","first-page":"6271","DOI":"10.1016\/j.vaccine.2007.05.054","article-title":"Single-dose, fast-acting vaccine candidate against western equine encephalitis virus completely protects mice from intranasal challenge with different strains of the virus","volume":"25","author":"Barabe","year":"2007","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2018.06.064_b0210","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1128\/jvi.62.12.4697-4702.1988","article-title":"Recombinant vaccinia virus\/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge","volume":"62","author":"Kinney","year":"1988","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2018.06.064_b0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026666","article-title":"Characterization of protection afforded by a bivalent virus-like particle vaccine against bluetongue virus serotypes 1 and 4 in sheep","volume":"6","author":"Perez de Diego","year":"2011","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.vaccine.2018.06.064_b0220","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.vaccine.2008.12.023","article-title":"A multi-valent vaccine approach that elicits broad immunity within an influenza subtype","volume":"27","author":"Huber","year":"2009","journal-title":"Vaccine"},{"issue":"44","key":"10.1016\/j.vaccine.2018.06.064_b0225","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1016\/j.vaccine.2009.08.022","article-title":"Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors","volume":"27","author":"Yu","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2018.06.064_b0230","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.4049\/jimmunol.1701088","article-title":"Simultaneous targeting of multiple hemagglutinins to APCs for induction of broad immunity against influenza","volume":"200","author":"Anderson","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.06.064_b0235","first-page":"2(4)","article-title":"Linkage of transcription and translation within cytoplasmic poxvirus DNA factories provide a mechanism to coordinate viral and usurp host functions","author":"Katsafranas","year":"2007","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2018.06.064_b0240","article-title":"Poxviruses: slipping and sliding through transcription and translation","volume":"13(11):https","author":"Walsh","year":"2017","journal-title":"PLOS Pathogen"},{"issue":"2","key":"10.1016\/j.vaccine.2018.06.064_b0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192312","article-title":"A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates","volume":"13","author":"Callendret","year":"2018","journal-title":"PloS One"},{"issue":"16","key":"10.1016\/j.vaccine.2018.06.064_b0250","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1016\/j.vaccine.2007.01.034","article-title":"Humanization and mammalian expression of a murine monoclonal antibody against Venezuelan equine encephalitis virus","volume":"25","author":"Hu","year":"2007","journal-title":"Vaccine"},{"issue":"34","key":"10.1016\/j.vaccine.2018.06.064_b0255","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1016\/j.vaccine.2010.06.038","article-title":"A recombinant humanized monoclonal antibody completely protects mice against lethal challenge with Venezuelan equine encephalitis virus","volume":"28","author":"Hu","year":"2010","journal-title":"Vaccine"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2018.06.064_b0260","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.vaccine.2005.01.032","article-title":"Efficacy of DNA vaccination against western equine encephalitis virus infection","volume":"23","author":"Nagata","year":"2005","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2018.06.064_b0265","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/135965350501000212","article-title":"Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption","volume":"10","author":"Harrer","year":"2005","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.vaccine.2018.06.064_b0270","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2217\/fvl.13.42","article-title":"Vaccine and therapeutics to the alphaviruses","volume":"8","author":"Nagata","year":"2013","journal-title":"Future Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18309058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18309058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:27:03Z","timestamp":1759400823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18309058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":54,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0264410X18309058"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.06.064","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protective efficacy of monovalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.06.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}